CIDRAP newsletters options
A team of researchers from Harvard is developing synthetic antibiotics enhanced to overcome resistance mechanisms.
Chlorination wasn't required for the city's water system, and city officials are developing a disinfection plan and considering their next steps.
The woman had bought a duck at a live market, and meat samples were positive for H10N5.
The NIH is investing $515 million more in its long COVID research program.
Adults and kids have, respectively, a 50% and 40% higher risk of having shortness of breath after recovery from COVID-19.
The case is the first outside of the Fairbanks area, suggesting wider circulation in small animals.
The results suggest that the flu virus may have a more specific role in destabilizing and rupturing atherosclerotic plaques, the researchers say.
The aim of the updated list is to reduce or restrict the use of medically important antibiotics in non-human sectors to preserve their effectiveness.
So far, the cases have been detected in 3 South African provinces and aren't fueling a resurgence in cases.
A population-based study in Shanghai finds COPD patients are nearly 8 times more likely to use antibiotics than the general population.
COVID-19 was associated with a 30% increased subsequent risk of a first cardiovascular event.
The patient is the brother of a boy who recently died from an H5N1 infection.
The authors acknowledge that the findings may have been influenced by confounding factors and bias.
As small clusters continue, the CDC notes that only 1 in 4 eligible people have received both mpox vaccine doses.
Influenza B activity is fueling rises in the Midwest and Central regions.
Diarrhea kills up to 500,000 children globally each year.
Outpatient visits of all types but surgery were higher among infected veterans than among their uninfected peers, with an increase of 5.1 per 30 days.
The study underscores the need for equitable access to vaccines, effective drugs, and mosquito-control efforts, the authors say.
Viremia findings also add support for the vaccine's use as postexposure prophylaxis.
Nirsevimab effectiveness was greater than 70% in infants under 9 months.
